Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8921049 | 1.00 | MAPT (0.38) | MAPTPKMLMNAALOX15BLM | |
| SCHEMBL18425941 | 0.80 | MAPT (0.38) | MAPTPKMLMNABLMPMP22 | |
| SCHEMBL18425940 | 0.78 | MAPT (0.37) | MAPTPKMLMNABLMPMP22 | |
| SCHEMBL14776189 | 0.78 | MAPT (0.40) | MAPTPKMALDH1A1TP53TSHR | |
| SCHEMBL14776192 | 0.78 | MAPT (0.40) | MAPTPKMALDH1A1TP53TSHR | |
| SCHEMBL24899669 | 0.76 | LMNA (0.37) | LMNAALOX15BLMPMP22ALDH1A1 | |
| SCHEMBL14776209 | 0.76 | ALDH1A1 (0.40) | MAPTPKMALDH1A1TP53TSHR | |
| SCHEMBL14776211 | 0.76 | ALDH1A1 (0.40) | MAPTPKMALDH1A1TP53TSHR | |
| SCHEMBL8923357 | 0.73 | HCAR2 (0.40) | MAPTPKMTSHR | |
| SCHEMBL8752313 | 0.73 | HCAR2 (0.40) | MAPTPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | THE UNIVERSITY OF MANCHESTER (GB) | 2020-02-25 | — | — | US | disclosed |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2018-08-02 | — | — | US | disclosed |
| EP-3328868-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | The University of Manchester (GB) | 2018-06-06 | — | — | EP | disclosed |
| WO-2017017469-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | THE UNIVERSITY OF MANCHESTER (GB) | 2017-02-02 | — | — | WO | disclosed |
| US-5614351-A | Radiation-curable mixture, and radiation-sensitive recording material produced therefrom for high-energy radiation | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-03-25 | — | — | US | disclosed |
| US-5217843-A | Containing acid cleavable compound and compound that forms acid when subjected to high energy radiation | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10570157-B2 | Cyclic diarylboron derivatives as NLRP3 inflammasome inhibitors | NLRP3, IL1B, NOD1 | MAPT 848/4885PKM 2708/4885LMNA 714/4885 |
| US-20180215772-A1 | CYCLIC DIARYLBORON DERIVATIVES AS NLRP3 INFLAMMASOME INHIBITORS | NLRP3, IL1B, NOD1 | MAPT 848/4885PKM 2708/4885LMNA 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.